586 related articles for article (PubMed ID: 9556058)
21. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
[TBL] [Abstract][Full Text] [Related]
23. Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Bivi N; Romanello M; Harrison R; Clarke I; Hoyle DC; Moro L; Ortolani F; Bonetti A; Quadrifoglio F; Tell G; Delneri D
Genome Biol; 2009; 10(9):R93. PubMed ID: 19744312
[TBL] [Abstract][Full Text] [Related]
24. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
Biochem Biophys Res Commun; 1999 Feb; 255(2):491-4. PubMed ID: 10049736
[TBL] [Abstract][Full Text] [Related]
25. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
Frith JC; Mönkkönen J; Auriola S; Mönkkönen H; Rogers MJ
Arthritis Rheum; 2001 Sep; 44(9):2201-10. PubMed ID: 11592386
[TBL] [Abstract][Full Text] [Related]
26. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
Rogers MJ
Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
[TBL] [Abstract][Full Text] [Related]
27. Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.
van Beek E; Löwik C; Karperien M; Papapoulos S
Bone; 2006 Feb; 38(2):167-71. PubMed ID: 16165408
[TBL] [Abstract][Full Text] [Related]
28. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Thompson K; Dunford JE; Ebetino FH; Rogers MJ
Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
[TBL] [Abstract][Full Text] [Related]
29. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
30. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
32. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.
Benford HL; Frith JC; Auriola S; Mönkkönen J; Rogers MJ
Mol Pharmacol; 1999 Jul; 56(1):131-40. PubMed ID: 10385693
[TBL] [Abstract][Full Text] [Related]
33. Cellular and molecular mechanisms of action of bisphosphonates.
Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro.
Töyräs A; Ollikainen J; Taskinen M; Mönkkönen J
Eur J Pharm Sci; 2003 Jul; 19(4):223-30. PubMed ID: 12885386
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
36. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.
Lehenkari PP; Kellinsalmi M; Näpänkangas JP; Ylitalo KV; Mönkkönen J; Rogers MJ; Azhayev A; Väänänen HK; Hassinen IE
Mol Pharmacol; 2002 May; 61(5):1255-62. PubMed ID: 11961144
[TBL] [Abstract][Full Text] [Related]
37. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
Dunford JE
Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates: from bench to bedside.
Russell RG
Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
40. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.
Sutherland KA; Rogers HL; Tosh D; Rogers MJ
Arthritis Res Ther; 2009; 11(2):R58. PubMed ID: 19405951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
